Home >> Marketplace Directory >> Fujirebio, Janssen team up

Fujirebio, Janssen team up

image_pdfCreate PDF

July 2018—Fujirebio has entered into an agreement with Janssen Pharmaceuticals to develop and commercialize an amyloid β 42/40 ratio assay. The assay will run on the Lumipulse series, a fully automated chemiluminescent enzyme immunoassay system, and is intended to help identify patients who may benefit from treatment with atabecestat, Janssen’s investigational oral BACE inhibitor. Atabecestat is being studied for the slowing of cognitive decline in people who are identified by biomarkers to be progressing to Alzheimer’s dementia.
Fujirebio, 844-544-3787
Janssen Pharmaceuticals, 800-526-7736

CAP TODAY
X